肾康注射液对链脲佐菌素诱导的大鼠DN的作用研究

目的:研究肾康注射液(SKI)对糖尿病肾病(DN)的作用。方法:采用大鼠腹腔注射链脲佐菌素65 mg/kg体重建立DN大鼠模型,SKI高、中、低分别腹腔注射SKI 10 m L/kg,5 m L/kg,2.5 m L/kg,2次/天;正常组和模型组分别给予生理盐水5 m L/kg,2次/天;8周后,观察、测量相应生化和病理等指标。结果:SKI可明显增强DN大鼠肾脏对血肌酐和血尿素氮的清除率,显著降低血液中总胆固醇、甘油三脂和低密度脂蛋白的含量和升高血液中高密度脂蛋白含量,显著升高血清中T-SOD和CAT的活力,降低血清中NO及MDA含量和降低血清中NOS的活力,显著改善糖尿病引起的肾组织损伤。结论:SKI对治疗DN的治疗作用是肯定的其主要表现在改善血脂代谢紊乱,增强机体抗氧化应激能力及增强肾脏对肌酐和尿素氮的清除能力进而改善肾脏损伤。     

丁咯地尔和α-硫辛酸对糖尿病大鼠肾功能的保护作用研究

目的：研究丁咯地尔和α-硫辛酸（ALA）对糖尿病（DM）大鼠肾功能的保护作用。方法：雄性SD大鼠用链脲佐菌素（60mg/kg）腹腔注射诱导DM。大鼠随机分为健康组（NC）、DM组（DMC）、DM＋ALA组（ALA组）、DM＋丁咯地尔组（丁咯地尔组）。ALA组和丁咯地尔组每天给予ALA100mg／kg灌胃和丁咯地尔（0．1g／kg）腹腔注射,NC组和DMC组大鼠给予等量生理盐水每日灌胃。干预4周后,测观察治疗后大鼠血糖、尿素氮、血肌苷,内生肌苷清除率、24小时尿蛋白排泄率,比色法检测血清抗氧化酶和丙二醛（MDA）含量。结果：①丁咯地尔和α-硫辛酸降低糖尿病大鼠的尿素氮、血肌苷、24h尿白蛋白排泄率、丙二醛,增加超氧化物歧化酶②两种药物联合用药具有协同作用。结论：丁咯地尔和ALA可能通过抑制机体氧化应激水平,减低早期DM大鼠肾脏损害。     

二苯乙烯苷对动脉硬化大鼠主动脉金属蛋白酶2，9表达的影响

目的：观察二苯乙烯苷（TSG）对动脉硬化大鼠主动脉基质金属蛋白酶2,9（MMP-,9）表达的影响,探讨TSG治疗动脉粥样硬化、稳定斑块的可能机制。方法：采用高脂饲料喂饲＋VitD3复制大鼠动脉粥样硬化模型。SD大鼠60只,雄性,随机分为6组（n=10）：正常组;阳性药组;模型组;TSG120mg·kg^-1·d^-1组;TSG60mg·kg^-1·d^-1组;TSG30,mg·kg^-1·d^-1组。造模给药12周后抽样检测大鼠主动脉,以大鼠动脉粥样硬化斑块形成为造模指标,经治疗6周后,蛋白免疫印迹、逆转录聚合酶反应法观察各组动脉MMP-2,9的蛋白和mRNA表达;检测血清GRP;ELISA法测定血清IL-6和TNF-α。结果：TSG120mg·kg^-1·d^-1和TSG60mg·kg^-1·d^-1能显著降低血清IL-6、TNF-α、CRP和动脉MMP-2,9表达,并呈剂量依赖性。结论：TSG对高脂饲料＋VitD3诱导大鼠动脉粥样硬化具有治疗与稳定斑块作用,其机制可能与其抗炎作用、调节基质金属蛋白酶表达有关.     

淫羊藿苷缓解腹部皮瓣缺血再灌注损伤模型大鼠的作用及机制研究

摘要 目的：研究淫羊藿苷缓解腹部皮瓣缺血再灌注损伤（IRI）模型大鼠的作用及机制。方法：取30只SD级大鼠作为研究对象,将其按照随机数字表法分作假手术组、模型组以及淫羊藿苷组,每组各10只。其中模型组和淫羊藿苷组大鼠均制作大鼠腹部皮瓣IRI模型,假手术组以及模型组大鼠予以生理盐水腹腔注射,淫羊藿苷组大鼠则予以淫羊藿苷腹腔注射。对比各组大鼠皮瓣存活面积及存活率、血清炎症因子以及氧化应激指标水平、皮瓣组织中p38丝裂原活化蛋白激酶（p38 MAPK）信号通路相关蛋白表达情况。结果：模型组、淫羊藿苷组大鼠的皮瓣存活面积及存活率均低于假手术组,但淫羊藿苷组大鼠的皮瓣存活面积及存活率均高于模型组（P＜0.05）。模型组、淫羊藿苷组大鼠血清白细胞介素-10（IL-10）均低于假手术组,但淫羊藿苷组高于模型组;模型组、淫羊藿苷组大鼠血清肿瘤坏死因子-?琢（TNF-?琢）均高于假手术组,但淫羊藿苷组低于模型组（P＜0.05）。模型组、淫羊藿苷组大鼠血清超氧化物歧化酶（SOD）、谷胱甘肽（GSH）水平均低于假手术组,但淫羊藿苷组大鼠血清SOD、GSH水平均高于模型组;模型组、淫羊藿苷组大鼠血清丙二醛（MDA）水平均高于假手术组,但淫羊藿苷组大鼠血清MDA水平低于模型组（P＜0.05）。模型组、淫羊藿苷组大鼠皮瓣组织p38 MAPK、丝裂原活化蛋白激酶磷酸酶-2（MKP-2）相对表达量均高于假手术组,但淫羊藿苷组皮瓣组织p38 MAPK相对表达量低于模型组,而MKP-2相对表达量高于模型组（P＜0.05）。结论：淫羊藿苷可通过调控p38 MAPK信号通路缓解炎症反应及氧化应激,发挥减轻腹部皮瓣IRI的作用。     

普罗布考对糖尿病大鼠肾组织氧化应激的影响

目的研究普罗布考（Probucol）对糖尿病大鼠肾组织氧化应激的影响。方法采用腹腔注射链脲佐菌素（STZ）建立糖尿病大鼠模型。30只Wistar大鼠分为正常对照组（NC）、糖尿病组（DM）、糖尿病普罗布考治疗组（DP）。8周末称取体重、肾重、计算肾肥大指数（肾重/体重）,检测尿白蛋白排泄率（UAER）;测定各组生化指标包括血糖（BG）、胆固醇（TC）、三酰甘油（TG）、血清肌酐（SCr）、血尿素氮（BUN）;检测肾组织中丙二醛（MDA）的含量及超氧化物歧化酶（SOD）、过氧化氢酶（CAT）与谷胱甘肽过氧化物酶（GSH-Px）活性;肾组织切片行PAS染色分析肾小球面积及肾小球体积。结果 DM组大鼠肾重、肾重/体重、UAER、TC、TG、SCr、BUN、肾小球面积、肾小球体积较NC组均明显增加,DP组上述改变较DM组均明显减轻（P〈0.05）。DP组肾组织中MDA含量明显低于DM组,SOD、CAT、GSH-Px活性明显高于DM组（P〈0.05）。结论普罗布考可能部分通过减轻肾组织氧化应激反应实现对糖尿病大鼠肾脏的保护作用。     

紫檀芪对2型糖尿病大鼠肾脏的影响

目的：研究紫檀芪对2型糖尿病大鼠肾脏的影响。方法：采用高糖高脂饮食结合小剂量链脲菌素构建2型糖尿病大鼠模型。将大鼠随机分为正常对照组、2型糖尿病组、紫檀芪低剂量组、紫檀芪中剂量组、紫檀芪高剂量组。干预7w后,检测大鼠血糖和血脂的变化,测定肾功能指标血尿素氮和血肌酐的含量及肾脏氧化应激水平,取肾脏组织做HE染色,观察大鼠肾组织病理学变化。结果：2型糖尿病组大鼠血糖、甘油三酯（TG）、总胆固醇（TC）、高密度脂蛋白胆固醇（LDL C）水平升高,低密度脂蛋白胆固醇（HDL C）水平降低;血尿素氮和血肌酐升高;肾脏组织的超氧化物歧化酶（SOD）活性下降,丙二醛（MDA）水平升高;肾组织局部可见大量炎性细胞灶性浸润,炎症灶周围肾小管上皮细胞广泛水肿。紫檀芪干预后,血糖、TG、TC、LDL C水平降低;血尿素氮和血肌酐降低;肾脏组织的SOD活性升高,MDA水平下降;肾小球和肾小管病变减轻。结论：紫檀芪能够降低血糖和血脂、血尿素氮和血肌酐,改善肾脏的病理损伤,对2型糖尿病大鼠肾脏的损伤具有一定的治疗作用。     

二苯乙烯苷对H202诱导血管内皮细胞ICAM-1及VCAM-1表达的影响

目的：通过研究二苯乙烯苷（TSG）对H20：诱导的人脐静脉内皮细胞ICAM-1、VCAM-1表达的影响,探明二苯乙烯苷抗氧化保护内皮细胞的作用机制。方法：体外培养人脐静脉内皮细胞,实验分为空白对照组、H20：组、辛伐他汀组、TSG组,运用逆转录聚合酶链式反应和酶联免疫吸附试验分别检测ICAM-1及VCAM-1mRNA与其蛋白的表达。结果：200μmol·L。的H202作用内皮细胞24h后。ICAM．1和VCAM-1的mRNA和蛋白表达水平均明显上调,与空白对照组比较,差异有显著性（P〈0．01）。而在200μmol·L。的H202作用前用1μmol·L^-1二苯乙烯苷预处理体外培养人脐静脉内皮细胞4h,结果显示二苯乙烯苷能抑制H2O2诱导的内皮细胞ICAM-1、VCAM-1的mRNA和VCAM-1的蛋白水平表达,与H2O2组比较差异有显著性（P〈0．01）;而ICAM-1的蛋白表达水平与H202组比较差异有统计学意义（P〈0．05）;辛伐他汀组ICAM-1和VCAM-1的mRNA及其蛋白水平表达降低,与H20：组比较差异均有显著性（P〈0．01）。实验结果表明二苯乙烯苷可抑制H2O2诱导的内皮细胞粘附分子ICAM-1、VCAM-1表达。结论：二苯乙烯苷可通过降低细胞粘附分子ICAM-1和VCAM-1的表达保护氧化应激引起的人脐静脉内皮细胞损伤。     

香椿子石油醚提取物对大鼠糖尿病肾病的保护作用

为了研究香椿子石油醚提取物(PEE)对糖尿病肾病(DN)大鼠的保护作用及初步机制,采用Wistar雄性大鼠,STZ 60 mg/kg造模。造模成功后,DN大鼠分为模型组、PEE干预组(5 mg/100 g·d),另设正常组。灌胃10周后处死,取材及采血,检测肾脏指数及生化指标;肾皮质行HE和PAS、PASM、Masson染色;电镜观察大鼠肾组织形态;免疫组化观察转化生长因子-β1(TGF-β1)、结缔组织生长因子(CTGF)、IV型胶原蛋白(collagen IV)表达水平。结果显示,PEE组大鼠血糖、尿蛋白、氧化应激指标下降;血肌酐与尿素氮降低,明显改善DN大鼠肾脏病理学异常,降低肾脏TGF-β1、CTGF、collagen IV蛋白表达。这表明PEE抑制氧化应激,减少TGF-β1、CTGF、collagen IV蛋白表达,对DN大鼠有一定保护作用。     

田蓟苷对脑小血管病大鼠模型认知功能受损和神经细胞凋亡的影响

摘要 目的：探讨田蓟苷对脑小血管病（cerebral small vessel disease,CSVD）大鼠模型认知功能受损和神经细胞凋亡的影响及机制。方法：将SD大鼠分为Sham组、CSVD组、低剂量田蓟苷组（L-Til组,5 mg/kg/d）、中剂量田蓟苷组（M-Til组,10 mg/kg/d）和高剂量田蓟苷组（H-Til组,20 mg/kg/d）。通过同种系微栓子体外注入法建立CSVD大鼠模型,各组大鼠均治疗4周。治疗结束后对各组大鼠进行Morris水迷宫测试,分离海马组织并进行HE染色、TUNEL染色和尼氏染色。通过免疫组化染色或Western blot检测大鼠海马组织中Bax、Bcl2、cleaved caspase-3、VEGF和细胞核NF-κB p65的表达。使用相应试剂盒检测血清炎症指标（TNF-α和IL-1β）和氧化应激指标（SOD和MDA）水平。结果：与CSVD组比较,L-Til组、M-Til组和H-Til组的逃避潜伏期均缩短,而穿越平台次数均增加（P<0.05）。与CSVD组比较,L-Til组、M-Til组和H-Til组大鼠海马组织TUNEL阳性率降低,而尼氏体光密度增加（P<0.05）;Bax和cleaved caspase-3的表达水平降低,Bcl2水平升高（P<0.05）。与CSVD组比较,L-Til组、M-Til组和H-Til组大鼠血清中TNF-α、IL-1β和MDA水平降低,SOD升高（P<0.05）。与CSVD组比较,L-Til组、M-Til组和H-Til组大鼠海马组织中细胞核NF-κB p65蛋白表达水平降低,细胞质VEGF蛋白表达水平升高（P<0.05）。结论：本研究证明田蓟苷可减轻CSVD大鼠的认知功能障碍并抑制神经细胞凋亡,田蓟苷对CSVD的治疗机制部分通过减少炎症和氧化应激、促进VEGF的表达和抑制NF-κB信号通路来实现。     

基于HMGB1/TLR4/NF-κB信号通路探讨忍冬苷对脓毒症肝损伤大鼠的影响

摘要 目的：基于高迁移率族蛋白B1（HMGB1）/Toll样受体4（TLR4）/核因子κB（NF-κB）信号通路探讨忍冬苷对脓毒症肝损伤大鼠的影响。方法：60只雄性SD大鼠随机分为模型组、对照组、阳性对照组（地塞米松10 mg/kg）、忍冬苷低剂量（7.5 mg/kg）、忍冬苷中剂量（15 mg/kg）、忍冬苷高剂量（30 mg/kg）组,每组10只。采用盲肠结扎穿刺法建立大鼠脓毒症模型。实验结束后麻醉大鼠取血制备血清,检测血清中超氧化物歧化酶（SOD）活性和丙二醛（MDA）、白介素-6（IL-6）、肿瘤坏死因子-α（TNF-α）、白介素-10（IL-10）含量;分离肝组织称重,计算肝脏指数,一部分用于HE染色观察肝组织病理变化,一部分用于制备组织匀浆检测组织中肝功能指标谷丙转氨酶（ALT）、天冬氨酸转氨酶（AST）活性及HMGB1、TLR4、NF-κB蛋白表达。结果：与对照组比较,模型组大鼠血清中MDA、TNF-α、IL-6含量、肝脏指数以及肝组织中AST、ALT活性、HMGB1、TLR4、NF-κB蛋白表达显著增加（P＜0.05）,SOD活性与IL-10含量显著下降（P＜0.05）;且肝组织出现明显病灶,肝细胞水肿变性,大量炎性细胞浸润。与模型组比较,阳性对照组与忍冬苷各剂量组大鼠血清中MDA、TNF-α、IL-6含量、肝脏指数以及肝组织中AST、ALT活性、HMGB1、TLR4、NF-κB蛋白表达显著降低（P＜0.05）,SOD活性与IL-10含量显著升高（P＜0.05）;忍冬苷低、中剂量组仍可见病灶和水肿,但病变减轻;地塞米松组与忍冬苷高剂量组肝细胞结构趋于正常,未发现病灶。与阳性对照组比较,忍冬苷低、中剂量组大鼠血清中MDA、TNF-α、IL-6含量、肝脏指数以及肝组织中AST、ALT活性、HMGB1、TLR4、NF-κB蛋白表达显著升高（P＜0.05）,SOD活性与IL-10含量显著降低（P＜0.05）;忍冬苷高剂量组上述指标无显著差异（P＞0.05）。结论：忍冬苷通过下调HMGB1/TLR4/NF-κB信号通路的表达,抑制氧化应激,减轻炎症反应,改善肝功能,发挥对脓毒症肝损伤的保护作用。     

早期糖尿病肾病大鼠模型磁共振弥散加权成像的初步研究

目的:探讨早期糖尿病肾病(Diabetic nephropathy,DN)模型大鼠磁共振弥散加权成像(Diffusion Weight Imaging,DWI)肾实质ADC值变化规律。方法:将20只清洁级雄性SD大鼠随机分成两组,糖尿病肾病组(DN组)12只,正常对照组(NC组)8只;DN组给予60 mg/kg链尿佐菌素腹腔注射诱导糖尿病肾病模型,NC组按照相同方法、相同剂量柠檬酸缓冲液腹腔注射;并对最终糖尿病模型造模成功并且存活的8只DN大鼠、8只NC大鼠进行MRI扫描,包括常规轴位T1WI、T2WI扫描及DWI扫描;扫描结束后收集血液送血肌酐及双肾组织进行病理检查。并测量每只大鼠双肾皮、髓质的ADC值。结果:造模后,DN组大鼠血糖明显升高、尿量明显增加、体重明显减低,DN组大鼠肾脏出现不同程度病理损伤,符合早期DN病理改变。DN组大鼠肾脏皮、髓质ADC值分别为1.522±0.913×10^-3 mm^2/s、1.268±0.388×10^-3 mm^2/s,较NC组肾脏皮、髓质ADC值1.276±0.341×10^-3 mm^2/s、1.011±0.217×10^-3 mm^2/s增高,两组比较有统计学意义(P<0.05)。结论:DWI成像ADC值可能反映早期糖尿病肾病肾脏功能的变化。     

Prevention of diabetic nephropathy in rats through enhanced renal antioxidative capacity by inhibition of the proteasome

AimsOxidative stress may play an important role in the pathogenesis of diabetic nephropathy (DN). Recent studies have shown that the ubiquitin–proteasome pathway (UPP) and oxidative stress have interaction. We aimed to investigate whether inhibiting the proteasome has a preventive effect on DN through suppression of renal oxidative stress.Main methodsMale Sprague–Dawley rats were randomly divided into three groups: a normal control (NC) group, a streptozotocin-induced DN model group, and a DN plus MG132 (10 μg/kg) treatment group.Key findingsIncreased 24-h urinary protein excretion rate (UPER) and renal pathological changes were all improved after MG132 administration. Furthermore, enhanced renal 26S proteasome activity and concentration in DN rats were effectively reduced after MG132 administration. Increased p47phox and nitrotyrosine (NT) expressions in kidneys of DN rats were decreased after MG132 treatment. Renal mRNA and protein expressions of NF-E2 related factor 2 (Nrf2) were up-regulated by MG132 in comparison to DN alone. Decreased renal mRNA expression of superoxide dismutase 1 (SOD1), catalase (CAT) and glutathione peroxidase (GPx) in DN rats was heightened after MG132 intervention. Depressed activities of renal SOD, CAT and GPx in DN rats were also improved by MG132 treatment. Increased renal nuclear factor κB (NF-κB) activity was inhibited after MG132 administration in DN rats at the end of 12 weeks.SignificanceOur present data suggest that inhibition of the proteasome by low-dose MG132 has a preventive effect on DN development and progression in rats through the up-regulation of antioxidant genes.     

Comparative hypoglycemic and nephroprotective effects of tocotrienol rich fraction (TRF) from palm oil and rice bran oil against hyperglycemia induced nephropathy in type 1 diabetic rats

Diabetic nephropathy (DN) is a serious complication confronted by patients with diabetes. Available data indicate that the development of DN is linked to hyperglycemia. Tocotrienol rich fraction (TRF) from palm oil (PO) and rice bran oil (RBO) has been shown to lower the blood glucose level in patients and preclinical animal models. This study was designed to investigate if TRF from PO and RBO could improve the renal function in DN by the virtue of their hypoglycemic and antioxidant activities. Male Wistar rats having an average body weight (bw) 250 g were divided into four groups of six each .The first group served as diabetic control [injected with 55 mg/kg bw of streptozotocin (STZ), intraperitoneally], while the second and third group received PO-TRF and RBO-TRF, respectively, by gavage at a dose of 200 mg/kg bw/day, over a period of 8 weeks post-induction of diabetes. The fourth group comprised of age-matched male Wistar rats that received single intraperitoneal injection of normal saline only and served as control. After 8 weeks of STZ injection and TRF treatment, 24 h urine was collected and animals were sacrificed. Fasting blood glucose, glycosylated hemoglobin, biochemical markers of renal function and oxidative stress were evaluated in serum, urine and kidney tissue. The results show that treatment with PO-TRF as well as RBO-TRF significantly improved the glycemic status and renal function in type 1 diabetic rats but PO-TRF afforded greater efficiency at similar dose as compared to RBO-TRF. In conclusion, PO-TRF was found to be more effective hypoglycemic and nephroprotective agent in DN than RBO-TRF.     

The renoprotective effects of berberine via the EP4-Gαs-cAMP signaling pathway in different stages of diabetes in rats

Abstract

Aims: To investigate the renoprotective roles of berberine (BBR) in different stages of diabetic nephropathy (DN) in streptozotocin (STZ)-induced diabetic rats fed a high-sugar and high-fat diet. Methods: Diabetes was induced in mice by intraperitoneal injection of STZ, and the mice were then randomly divided into groups: normal, diabetes, high-sugar and high-fat and BBR (high, median and low dose) groups. The body weight (BW), kidney weight to body weight (KW/BW), blood urea nitrogen, urine total protein to urine creatinine ratio and serum creatinine were measured on different weeks throughout the study. The protein levels of E prostanoid receptor 4 (EP4), Gαs and content of cAMP in the kidney were, respectively, detected by western blot analysis and RIA analysis. Results: In the DN rats, there was remarkable renal damage. BBR restored renal functional parameters, suppressed alterations in histological and ultrastructural changes in the kidney tissues and increased EP4, Gαs and cAMP levels compared with those of the DN model group. In addition, BBR has different therapeutic effects during the different stages of the development of DN, and it works best in the sixth week. Conclusion: These studies demonstrate, for the first time, that BBR exerts renoprotective effects in different stages of DN via EP4- Gαs- AC-cAMP signaling pathway in STZ-induced DN rats fed a high-sugar and high-fat diet.     

金樱子提取液对糖尿病肾病大鼠的肾脏保护作用

目的:研究金樱子提取液对糖尿病肾病(Diabetic Nephropathy,DN)大鼠的肾脏保护作用。方法:在高糖高脂饲料喂食SD(Sprague-Dawley)大白鼠的基础上腹腔注射链脲佐菌素(streptozotocin,STZ)诱导糖尿病肾病大鼠模型,随机分为糖尿病肾病模型组(DN组)和金樱子治疗组(DN+RLM组),同时另设正常对照组(NC组)和金樱子对照组(NC+RLM组)。检测金樱子提取液对各组大鼠血糖(fasting blood-glucose,FBG)、糖化血红蛋白(glycosylated haemoglobin,GHb)、24小时尿微量白蛋白和尿量、血尿素氮(BUN)、血肌酐(Scr)、胆固醇(TC)、甘油三酯(TG)及肾脏结构的影响。结果:与DN大鼠相比,糖尿病肾病大鼠经金樱子提取液治疗后,大鼠FBG、GHb水平、24 h尿微量白蛋白、24 h尿量、肾脏指数明显降低,血脂紊乱、肾功能损害以及DN肾脏病理明显改善,且无明显副作用。结论:金樱子提取液可明显降低DN大鼠血糖,改善DN大鼠血脂、肾功能紊乱及肾脏病理变化,对糖尿病大鼠肾脏具有较强的保护作用。     

硫化氢对1型糖尿病大鼠肾脏的保护作用

目的：观察硫化氢（H₂S）对1型糖尿病大鼠肾脏的保护作用及其机制。方法：32只雄性SD大鼠随机分为4组：正常对照（NC）组、糖尿病（DM）组、糖尿病治疗（NaHS+DM）组和NaHS对照（NaHS）组（n=8）。DM组和NaHS+DM组大鼠采用链脲佐菌素（STZ）55 mg/kg腹腔注射诱导1型糖尿病模型。造模成功后,NaHS+DM组和NaHS组采用腹腔注射NaHS溶液56 μmol/kg干预治疗。8周后,测定大鼠24 h尿蛋白含量、肾重指数、空腹血糖、尿素氮、肌酐等指标;HE染色观察肾脏组织形态学变化;测定肾脏组织脂质过氧化物丙二醛（MDA）含量、超氧化物歧化酶（SOD）和Caspase-3的活性;Western blot检测肾脏组织Bcl-2和Bax蛋白表达。结果：与NC组相比,NaHS组各项指标均无显著差异,DM组,24 h尿蛋白含量、肾重指数、空腹血糖、尿素氮和肌酐水平均明显升高;HE染色结果显示肾小球基底膜增厚、系膜基质增多;MDA含量、Caspase-3活性和Bax蛋白表达明显增高;SOD活性和Bcl-2蛋白表达显著降低。与DM组相比,NaHS+DM组肾功能损伤明显减轻,肾脏组织形态学变化明显改善,MDA含量、Caspase-3活性和Bax蛋白表达明显下降,SOD活性和Bcl-2蛋白表达显著增高。结论：H₂S对1型糖尿病大鼠肾脏具有保护作用,其机制可能与抑制氧化应激和细胞凋亡有关。     

益气化湿通络方对实验性肾功能衰竭大鼠肾脏氧化应激损伤及纤维化的改善作用

目的:观察益气化湿通络方对5/6肾切除肾衰竭模型大鼠残留肾脏氧化应激损伤及纤维化的改善作用。方法:采用Platt法建立5/6肾切除慢性肾衰竭大鼠模型。术后2周抽检大鼠确认造模成功后,将大鼠随机分为:模型组(Model)、益气化湿通络方组(YHT)、贝那普利组(BH)、假手术组(Sham),每组8只。每日灌胃治疗1次(YHT组免煎颗粒水溶液0.276 g/100 g;BH组盐酸贝那普利片剂水溶液0.09 mg/100 g灌胃;Sham及Model 1 ml/100 g生理盐水灌胃),连续治疗12周。12周末用代谢笼收集24 h尿液,检测尿蛋白含量。之后麻醉大鼠腹主动脉取血、摘取肾脏,检测血清血肌酐(Scr)、血尿素氮(BUN)含量;HE、Masson染色观察左肾病理改变;检测肾组织匀浆超氧化物歧化酶(SOD)的活性和丙二醛(MDA)的含量,检测肾组织中核因子NF-E2相关因子(Nrf2)、Kelch样环氧氯丙烷相关蛋白-1(Keap1)、NADPH氧化酶4(Nox4)、转化生长因子-β1(TGF-β1)、I型胶原蛋白(Collagen1)的表达以及Nrf2在肾组织细胞核内的表达。结果:与Sham组比较,Model组大鼠肾小球损伤较重,纤维化明显;Scr、BUN、MDA水平和24 h尿蛋白的排出量,Keap1、Nox4、TGF-β1、Collagen1的蛋白表达均明显升高(P＜0.01),SOD活性、Nrf2表达明显降低(P＜0.01);与Model组比较,经YHT或BH干预后肾小球病变程度减轻,纤维化较少,Scr、BUN、MDA水平和24 h尿蛋白的排出量,Keap1、Nox4、TGF-β1、Collagen1的蛋白表达均明显减少(P＜0.01),SOD活性、Nrf2表达明显升高(P＜0.01)。结论:益气化湿通络方通过影响Nrf2/Keap1信号通路、下调TGF-β1蛋白表达,从而改善肾衰竭模型大鼠残留肾脏的氧化应激损伤及纤维化程度。     

人参皂甙Rg3对糖尿病肾病大鼠生化指标及病理的影响

目的:探讨人参皂苷Rg3对糖尿病肾病大鼠生化指标及病理改变的影响。方法:30只SD雄性大鼠按随机数字表法分为正常对照组、模型对照组和人参皂甙Rg3组。采用链脲佐菌素建立糖尿病肾病大鼠模型。造模成功后,Rg3治疗组每天以Rg3(0.5mg/kg)灌胃,余予以等量蒸馏水灌胃。30天后分别测3组大鼠血糖、24小时尿蛋白、血肌酐,并予以HE染色行肾组织活检。结果:与正常组比较,模型对照组大鼠血糖、24小时尿蛋白、血肌酐明显升高,肾小球体积增大,基底膜增厚、细膜基质增多,肾小球内炎细胞浸润(P0.01)。与模型对照组比较,人参皂甙Rg3组血糖、24小时尿蛋白、血肌酐明显降低,肾小球基底膜增厚程度减轻,细胞外基质堆积减少,差异具有显著性(P0.05)。结论:人参皂甙Rg3能显著降低糖尿病大鼠血糖、血肌酐、24 h尿蛋白,能改善其肾脏的病理损害。     

Involvement of vascular endothelial nitric oxide synthase in development of experimental diabetic nephropathy in rats

Endothelial nitric-oxide synthase (eNOS) acts as a common pathogenic pathway in diabetic nephropathy (DN). However, its functional consequences are still not fully understood. Caveolin, a membrane protein, inhibits the eNOS by making caveolin-eNOS complex, and its expression is upregulated during diabetes mellitus (DM). This study was designed to determine the role of caveolin in eNOS-mediated NO synthesis and release in DN. DM in rat was induced by feeding of high-fat diet (HFD) for 2 weeks, followed by single dose of streptozotocin (STZ) (35 mg/kg, ip) further followed by HFD for further 8 weeks. Serum nitrite/nitrate ratio was measured to determine the plasma level of NO. Diabetic rat, after 6 weeks of STZ, developed elevated level of BUN, protein in urine, urinary output, serum creatinine, serum cholesterol, kidney weight, kidney weight/body weight, and renal cortical collagen content, while serum nitrite/nitrate concentration was significantly decreased as compared to normal control group. Treatment with sodium nitrite (NO donor), L: -arginine (NO precursor), daidzein (caveolin inhibitor), and combination of L: -arginine and daidzein for 2 weeks markedly attenuated these changes and increased serum nitrite/nitrate ratio. However, treatment with L-NAME, a eNOS inhibitor, significantly attenuated the L: -arginine-, daidzein-, or combination of L: -arginine and daidzein-induced ameliorative effects in DN. The finding of this study suggests that caveolin plays a vital role in the eNOS-mediated decrease in renal level of NO, which may be responsible for the development of DN in rats.